Abstract
388 (PB376): KO-2806, a next-generation farnesyl transferase inhibitor, re-sensitizes KRAS G12C NSCLC tumors to KRAS G12C mutant-specific inhibitors through mTOR signaling inhibition
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have